Author:
Gu Ruo-lan,Liu Liang,Xie Liang-zhi,Gai Wen-lin,Cao Si-shuo,Meng Zhi-yun,Gan Hui,Wu Zhuo-na,Li Jian,Zheng Ying,Zhu Xiao-xia,Dou Gui-fang
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference34 articles.
1. Christiansen ML, Balling KW, Persson E, Hilden I, Bagger-Sørensen A, Sørensen BB, et al. Functional characteristics of N8, a new recombinant FVIII. Haemophilia 2010; 16: 878–87.
2. Oldenburg J . Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125: 2038–44.
3. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44.
4. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK . Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; 7: CD 003429.
5. Key NS, Negrier C . Coagulation factor concentrates: past, present, and future. Lancet 2007; 370: 439–48.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献